BRUKINSA patients can call the myBeiGene^® patient support program to talk to a dedicated nurse: 1-833-BEIGENE (1-833-234-4363)

POWERFUL AND DURABLE RESPONSES

Adults with WM rapidly achieved high response rates regardless of line of therapy or mutation.

POWERFUL AND CONSISTENT RESPONSES WITH BRUKINSA ACROSS ALL WM PATIENTS

While the primary endpoint of superiority did not reach statistical significance, numerically higher VGPR rates were achieved in the BRUKINSA treatment arm.¹Initial analysis (19 months)²

VGPR/CR/PR data for BRUKINSA® (zanubrutinib) vs ibrutinib

In all patients, median time to response (CR+VGPR+PR) was 2.8 months for the BRUKINSA arm and 2.9 months for the ibrutinib arm.³

The median follow-up time was 19.4 months.²

The prespecified efficacy outcome measure of VGPR/CR was assessed by IRC.¹

*IWWM-6 criteria (Owen et al, 2013) requires complete resolution of extramedullary disease (EMD) if present at baseline for VGPR to be assessed. Modified IWWM-6 criteria (Treon, 2015) requires a reduction in EMD if present at baseline for VGPR to be assessed.^4,5

^†There were no CRs in either treatment arm.

CI=confidence interval; CR=complete response; IRC=independent review committee; IWWM-6=6th International Workshop on Waldenström’s Macroglobulinemia; PR=partial response; VGPR=very good partial response; WM=Waldenström’s macroglobulinemia.

SEE STUDY DESIGNS

CONSISTENT RESPONSES WITH BRUKINSA REGARDLESS OF LINE OF THERAPY

Initial analysis (19 months)²

$ORR data for BRUKINSA® (zanubrutinib) vs ibrutinib in treatment-naïve and relapsed/refractory subgroups$

All subgroup analyses are exploratory and descriptive in nature.

The median follow-up time was 19.4 months.²

^‡Responses were determined using modified IWWM-6 criteria.

^§There were no CRs in either treatment arm.

CI=confidence interval; CR=complete response; IWWM-6=6th International Workshop on Waldenström’s Macroglobulinemia; MR=minor response; ORR=overall response rate; PR=partial response; VGPR=very good partial response.

CONSISTENT RESPONSES WITH BRUKINSA REGARDLESS OF MUTATION

Initial analysis (19 and 18 months, respectively)^2,6

Consistent response data for BRUKINSA® (zanubrutinib) in subgroups with MYD88 mutations

All analyses are exploratory and descriptive in nature.

The median follow-up time was 19.4 months for Cohort 1 and 17.9 months for Cohort 2.^2,6

^¶Responses were determined using modified IWWM-6 criteria.

^#There were no CRs in either treatment arm.

CR=complete response; IWWM-6=6th International Workshop on Waldenström’s Macroglobulinemia; MUT=mutated; PR=partial response; VGPR=very good partial response; WHIM=WHIM syndrome-like somatic mutation; WT=wild type.

RESPONSES CONTINUED OVER TIME REGARDLESS OF MUTATION

Long-term analysis (44 months and 43 months, respectively)⁷

Consistent response data over time for BRUKINSA® (zanubrutinib) in subgroups with MYD88 mutations

All analyses are exploratory and descriptive in nature.

The median follow-up time was 44.4 months for Cohort 1 and 42.9 months for Cohort 2.⁷

**Responses were determined using modified IWWM-6 criteria.

^††In Cohort 2, 1 patient demonstrated a CR at 42.9-month follow-up.

CR=complete response; IWWM-6=6th International Workshop on Waldenström’s Macroglobulinemia; MRR=major response rate; MUT=mutated; PR=partial response; VGPR=very good partial response; WT=wild type.

DURABLE DISEASE CONTROL
WITH BRUKINSA

Sustained responses in patients who achieved a response (CR+VGPR+PR)

Initial analysis (19 months)²

Event-free rate at 12 months for BRUKINSA® (zanbrutinib) vs ibrutinib

All subgroup analyses are exploratory and descriptive in nature.

Median duration of response (VGPR/CR) was not reached in either treatment arm.²

The median follow-up time was 19.4 months.²

At 2 years: Event-free duration of CR+VGPR for BRUKINSA was higher (90.6%; range 73.6%, 96.9%) vs ibrutinib (79.3%; range 53.5%, 91.8%)⁷

CI=confidence interval; CR=complete response; PR=partial response; VGPR=very good partial response.

CONSISTENT RESPONSES CONTINUE WITH BRUKINSASTUDY 003: A PHASE 1/2 SUPPORTIVE STUDY⁸

A Phase 1/2, open-label, multicenter, single-arm trial including 77 patients with treatment-naïve and relapsed/refractory WM^‡‡

Data are consistent with results observed in ASPEN (Study 302) and the overall safety profile of BRUKINSA.⁸

Median follow-up time was 24 months in patients with treatment-naïve WM and 36 months in patients with R/R WM.⁸

^‡‡Assessed by IRC using modified IWWM-6 criteria.

^§§There was 1 CR in the study.

CI=confidence interval; CR=complete response; IRC=independent review committee; IWWM-6=6th International Workshop on Waldenström’s Macroglobulinemia; MR=minor response; ORR=overall response rate; PR=partial response; R/R=relapsed/refractory; VGPR=very good partial response; WM=Waldenström’s macroglobulinemia.

FLEXIBLE
DOSING

DOSING

ESTABLISHED
SAFETY PROFILE

SAFETY

PERSONALIZED
PATIENT SUPPORT

VISIT MYBEIGENE.COM

IMPORTANT SAFETY INFORMATION

What should I tell my healthcare provider before taking BRUKINSA?

Before taking BRUKINSA, tell your healthcare provider about all of your medical conditions, including if you:

have bleeding problems.
have had recent surgery or plan to have surgery. Your healthcare provider may stop BRUKINSA for any planned medical, surgical, or dental procedure.
have an infection.
have or had heart rhythm problems.
have high blood pressure.
have liver problems, including a history of hepatitis B virus (HBV) infection.
are pregnant or plan to become pregnant. BRUKINSA can harm your unborn baby. If you are able to become pregnant, your healthcare provider may do a pregnancy test before starting treatment with BRUKINSA.

Females should avoid getting pregnant during treatment and for 1 week after the last dose of BRUKINSA. You should use effective birth control (contraception) during treatment and for 1 week after the last dose of BRUKINSA.
Males should avoid getting female partners pregnant during treatment and for 1 week after the last dose of BRUKINSA. You should use effective birth control (contraception) during treatment and for 1 week after the last dose of BRUKINSA.

are breastfeeding or plan to breastfeed. It is not known if BRUKINSA passes into your breast milk. Do not breastfeed during treatment with BRUKINSA and for 2 weeks after the last dose of BRUKINSA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking BRUKINSA with certain other medications may affect how BRUKINSA works and can cause side effects.

What are the possible side effects of BRUKINSA?

BRUKINSA may cause serious side effects, including:

Bleeding problems (hemorrhage). Bleeding problems are common with BRUKINSA, and can be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs or symptoms of bleeding, including:

blood in your stools or black stools (looks like tar)
pink or brown urine
unexpected bleeding, or bleeding that is severe or you cannot control
vomit blood or vomit that looks like coffee grounds
cough up blood or blood clots
increased bruising
dizziness
weakness
confusion
change in speech
headache that lasts a long time

Infections that can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, or flu-like symptoms.
Decrease in blood cell counts (white blood cells, platelets, and red blood cells). Your healthcare provider should do blood tests during treatment with BRUKINSA to check your blood counts.
Second primary cancers. New cancers have happened in people during treatment with BRUKINSA, including cancers of the skin or other organs. Your healthcare provider will check you for other cancers during treatment with BRUKINSA. Use sun protection when you are outside in sunlight.
Heart rhythm problems (atrial fibrillation, atrial flutter, and ventricular arrhythmias) that can be serious and may lead to death. Tell your healthcare provider if you have any of the following signs or symptoms:

your heartbeat is fast or irregular
feel lightheaded or dizzy
pass out (faint)
shortness of breath
chest discomfort

Liver problems. Liver problems, which may be severe or life-threatening, or lead to death, can happen in people treated with BRUKINSA. Your healthcare provider will do blood tests to check your liver before and during treatment with BRUKINSA. Tell your healthcare provider or get medical help right away if you have any signs of liver problems, including stomach pain or discomfort, dark-colored urine, or yellow skin and eyes.

The most common side effects of BRUKINSA include:

decreased white blood cell count
decreased platelet count
upper respiratory tract infection
bleeding
muscle, bone, or joint pain

These are not all the possible side effects of BRUKINSA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is BRUKINSA?

BRUKINSA is a prescription medicine used to treat adults with:

Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Waldenström’s macroglobulinemia (WM).
Mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.
Follicular lymphoma (FL), in combination with the medicine obinutuzumab, when the disease has come back or did not respond to treatment and who have received at least two prior treatments.

It is not known if BRUKINSA is safe and effective in children.

Please see full Prescribing Information including Patient Information.

References: 1. BRUKINSA. Package insert. BeiGene USA, Inc.; 2024. 2. Tam CS, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038-2050. 3. Data on ﬁle. BeiGene USA, Inc. 4. Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenström macroglobulinemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171-176. 5. Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2015;126(6):721-732. 6. Dimopoulos M, Sanz RG, Lee HP, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020;4(23):6009-6018. 7. Tam CS, Garcia-Sanz R, Opat S, et al. ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. Poster presented at: American Society of Clinical Oncology (ASCO) 2022 Annual Meeting; June 3-7, 2022. Abstract 7521. 8. Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027-2037.

Want to learn about a different indication?

CLL/SLL MCL MZL FL

BRUKINSA for WM The BRUKINSA Difference

Study Design Efficacy Safety